Budesonide inhalation — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Asthma

• Albuterol HFA
• Montelukast
• Albuterol HFA 90 mcg/actuation inhaler
• Montelukast 4/5/10 mg tabs

About Budesonide inhalation

Budesonide inhalation is a vital medication for managing chronic respiratory conditions, helping countless individuals breathe more freely. At TheDrugClub, we believe essential medications should be accessible and affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Budesonide inhalation is approved for (FDA label)

Budesonide inhalation suspension is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age () Limitations of Use: Not indicated for the relief of acute bronchospasm () 1.1 Maintenance Treatment of Asthma Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use: • Budesonide inhalation suspension is NOT indicated for the relief of acute bronchospasm.

Source: Read the full FDA label on DailyMed. Label effective date: March 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Budesonide inhalation (FDA label)

For inhalation only. Do not swallow. Only use budesonide inhalation suspension with a jet nebulizer machine that is connected to an air compressor. Do not use with an ultrasonic nebulizer.

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Budesonide inhalation (FDA label)

Budesonide inhalation suspension is available in single strength: 0.5 mg/ 2mL. Budesonide inhalation suspension is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose ampules together with patient instructions for use. There are 30 ampules in a carton. Each single-dose ampule contains 2 mL of sterile liquid suspension. Inhalation suspension: 0.5 mg/ 2mL ()

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Budesonide inhalation (FDA label)

Systemic and inhaled corticosteroid use may result in the following: • Candida albicans Infection [see Warnings and Precautions ( 5.1 )] • Hypersensitivity Reactions Including Anaphylaxis [see Warnings and Precautions ( 5.3 )] • Immunosuppression [see Warnings and Precautions ( 5.4 )] • Hypercorticism and Adrenal Suppression [see Warnings and Precautions ( 5.6 )] • Reduction in Bone Mineral Density [see Warnings and Precautions ( 5.7 )] • Growth Effects in Pediatric Patients [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.4 )] • Glaucoma, Increased Intraocular Pressure and Cataracts [see Warnings and Precautions ( 5.9 )] • Eosinophilic Conditions and Churg-Strauss Syndrome [see Warnings and Precautions ( 5.11 )] Most common adverse reactions (incidence of ≥3%) are respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, rash ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Budesonide inhalation (FDA label)

The use of budesonide inhalation suspension is contraindicated in the following conditions: • Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. • Hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see Warnings and Precautions ( 5.3 ), Description ( 11 ), Adverse Reactions ( 6.2 )]. • Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required ( 4 ) • Hypersensitivity to any of the ingredients in budesonide inhalation suspension ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Budesonide inhalation (FDA label)

• Localized Infections: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation ( 5.1 ) • Deterioration of Disease and Acute Asthma Episodes: Do not use for the relief of acute bronchospasm ( 5.2 ) • Hypersensitivity Reactions: Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of budesonide inhalation suspension. Discontinue budesonide inhalation suspension if such reactions occur ( 5.3 ) • Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients ( 5.4 ) • Transferring Patients from Systemic Corticosteroid Therapy: Risk of impaired adrenal function when transferring from oral steroids.

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Budesonide inhalation (FDA label)

• Strong Cytochrome P450 3A4 Inhibitors (e.g., ritonavir): Use with caution. May cause increased systemic corticosteroid effects. ( 5.12 , 7.1 ) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the coadministration of budesonide inhalation suspension with long- term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions ( 5.12 ), Clinical Pharmacology ( 12.3 )].

Source: FDA prescribing information (DailyMed). Set ID: dd74e446-7c1b-4f02-9c73-ba716572ee77. SPL document ID: 3b3a9e87-3f6a-4168-a2bc-04feee0ae479. Label effective date: March 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.